WWW.LIB.KNIGI-X.RU
    -
 

Pages:     | 1 |   ...   | 2 | 3 ||

: , , ...

-- [ 4 ] --

163. Deicher, R. New insights into the regulation of iron homeostasis/ R. Deicher, W.H. Horl// Europ. J. Clin. Inv. 2006. Vol. 36. P. 301308.

164. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factoralpha/ O.A. Tsopra, P.G Ziros, E.D. Lagadinou [et al.]// Acta Haematol. 2009. Vol. 121, 4. P. 187195.

165. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?/ M. Henke, D. Mattern, M. Pepe [et al.]// J. Clin. Oncol. 2006. Vol. 24, 29. P. 47084713.

166. Dreyfus, F. The deleterious of iron overload in patients with myelodysplastic syndroms/ F. Dreyfus// Blood Rev. 2008. Vol. 22 (Suppl. 2). S.2934.

167. Droge, W. Free radicals in the physiological control of cell function/ W. Droge// Physiol. Rev. 2002. Vol. 82. P. 4795.

168. Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure/ A.

Quints-Cardama, F.P. De Souza Santos, H. Kantarjian [et al.]// Cancer. 2009. Vol.

115, 17. P. 39353943.

169. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients/ S. Park, C. Kelaidi, R.

Sapena [et al.]// Leuk. Res. 2010. Vol. 34, 11. P. 14301436.



170. Effects of Epoetin- on Quality of Life of Cancer Patients with Solid Tumors Receiving Chemotherapy/ C. Christodoulou, U. Dafni, G. Aravantinos [et al.]// Anticancer Research. 2009. Vol. 29. P. 693702.

171. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer/ M.S Aapro, W. Jelkmann, S.N. Constantinescu, B.

Leyland-Jones// Br. J. of Cancer. 2012. Vol. 106, 7. P. 12491258.

172. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study/ M. Hedenus, M. Adriansson, J. San Miguel [et al.]// Br. J. Haematol. 2003. Vol. 122. P. 394403.

173. Efficacy of a combination of human recombinant erythropoietin +13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes/ D. Ferrero, A. Darbesio, V. Giai [et al.]/ Br. J. Haematol. 2009. Vol. 144, 3. P. 342349.

174. Efficacy of Darbepoetin Alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies/ T.J.

Littlewood, J.D. Kallich, J. San Miguel [et al.]// Journal of Pain and Symptom Management. 2006. Vol. 31, 4. P. 317325.

175. Elliot, S. The effect of erythropoietin on normal and neoplastic cells/ S. Elliot, A.M. Sinclair // Biologics: Targets and Therapy. 2012. Vol. 6. P. 163189.

176. EORTC guidelines for the use of erythropoietic proteins in anemic patients with cancer: 2006 update/ C. Bokemeyer, M.S. Aapro, A. Courdi [et al.]// Eur. J. Cancer. 2007. Vol. 43. P. 258270.

177. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells/ . Hart, J. Grassinger, R. Andreesen, B. Hennemann// Bone Marrow Transplant. 2009. Vol.





43, 3. P. 197206.

178. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial/ M. E. Cabanillas, H.

Kantarjian, D.A. Thomas [et al.]// Cancer. 2012. Vol. 118, 3. P. 848855.

179. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes/ J. Glaspy, J. Crawford, J. Vansteenkiste [et al.]// Br. J. Cancer. 2010. Vol. 102, 2. P. 301315.

180. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells/ S.M. Kumar, H. Yu, D. Fong [et al.]// Melanoma Res. 2006. Vol.

16, 4. P. 275283.

181. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome/ M. Jadersten, L. Malcovati, I.

Dybedal [et al.]// J. Clin. Oncol. 2008. Vol. 26, 21. P. 36073613.

182. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury/ M. L. Brines, P. Ghezzi, S. Keenan [et al.]// Proc. Natl. Acad. Sci. USA.

2000. Vol. 97, 19. P.1052610531.

183. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings/ E. Kaptanoglu, I. Solaroglu, O.

Okutan [et al.]// Neurosurg. Rev. 2004. Vol. 27, 2. P. 113120.

184. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor-mediated neovascularization/ B.D. Westenbrink, E.

Lipsic, P. Van der Meer [et al.]// Eur. Heart J. 2007. Vol. 28. P. 20182027.

185. Erythropoietin in clinical practice: current use, effect on survival, and future directions/ H.S. Oster, M. Hoffman, S. Prutchi-Sagiv [et al.]// IMAJ. 2006. 8. P. 703706.

186. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase/ J.

Cortes, S. O'Brien, A. Quintas [et al.]// Cancer. 2004. Vol. 100, 11. P. 2396 2402.

187. Erythropoietin protects against ischaemic acute renal injury/ D.A. Vesey, C.

Cheung, B. Pat [et al.]// Nephrol. Dial. Transplant. 2004. 19, 2. P. 348355.

188. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemiareperfusion injury/ G.L. Wright, P. Hanlon, K. Amin [et al.]// FASEB J. 2004. Vol.

18, 9. P. 10311033.

189. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span/ P.E.

Sanchez, F.P. Navarro, R.P. Fares [et al.]// J. Comp. Neurol. 2009. Vol. 514, 4. P. 403414.

190. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial/ M. Henke, R. Laszig, C. Rube [et al.]// Lancet. 2003. Vol. 362. P. 12551260.

191. Erythropoietin treatment of anemia associated with multiple myeloma/ H.

Ludwig, E. Fritz, H. Kotzmann [et al.]// N. Engl. J. Med. 1990. Vol. 322. P.

16931699.

192. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature/ F. Cervantes, A.

Alvarez-Larrn, J.C. Hernndez-Boluda [et al.]// Br. J. Haematol. 2004. Vol. 127, 4. P. 399403.

193. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line/ Z.

Shi, V.M. Hodges, E.A. Dunlop [et al.]// Mol. Cancer Res. 2010. Vol. 8, 4. P.

615626.

194. Esquerdo, G. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatiguespecific quality of life questionnaire scores and change in haemoglobin level/ G.

Esquerdo, C. Llorca, J.M.Cervera// Clin. Transl. Oncol. 2011. Vol. 13, 5. P.

341347.

195. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial/ C.P. Miller, K.A. Clowe, K. Valliant-Saunders [et al.]// Stem. Cells. 2009. Vol. 27, 9. P. 23532361.

196. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma/ E.

Katodritou, M. Speletas, K. Zervas [et al.]// Lab. Hematol. 2006. Vol. 12, 1. P.4754.

197. Eve, H.E. Autoimmune haemolytic anaemia associated with mantle cell lymphoma/ H.E. Eve, S.A. Rule// Int. J. Hematol. 2010. Vol. 91, 2. P. 322 325.

198. Expression of erythropoietin and its receptor in neuroblastomas/ H. Sartelet, M.

Fabre, M. Castaing [et al.]// Cancer. 2007. Vol. 110, 5. P. 10961106.

199. Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role hypoxia in tumorigenesis/ Z. Gombos, L. Danihel, V. Repiska [et al.]// Indian J. Pathol. Microbiol. 2011. Vol. 5, 2. P. 273278.

200. Ferritin for the clinician/ M.A. Knovich, J.A. Storey, L.G. Coffman, S.V. Torti// Blood Rev. 2009. Vol. 23. P. 95104.

201. Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS/ S. Park, R. Sapera, C. Keladi [et al.]// Leuc. Res. 2011. Vol. 35. P. 15301533.

202. Five-year follow-up of imatinib therapy for newly diagnosed myeloid leukemia in chronic-phase shows sustained responses and high overall survival/ B.J. Druker, F.

Guilhot, S.G. O'Brien [et al.]// New Engl. J. Med. 2006. Vol. 355. P. 24082417.

203. Fleming, R.E. Ferroprotein mutation in autosomal dominant hemochromatosis:

loss of function, gain in understanding/ R.E. Fleming, W.S. Sly// J. Clin. Inv. 2001. Vol. 108. P. 521522.

204. Frequency and significance of anemia in non-Hodgkins lymphoma patients/ I.

Moullet, G. Salles, N. Ketterer [et al.]// Ann. Oncol. 1998. Vol. 9. P. 11091115.

205. Functional erythropoietin autocrine loop in melanoma/ S.M. Kumar, G. Acs, D.

Fang [et al.]// Am. J. Pathol. 2005. Vol. 166, 3. P. 823830.

206. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells/ A.M. Sinclair, A. Coxon, I. McCaffery [et al.]// Blood. 2010. Vol. 115, 21. P. 42644272.

207. Galinsky, I. Practical management of dasatinib for maximum patient benefit/ I.

Galinsky, S. Buchanan// Clin. J. Oncol. Nurs. 2009. Vol. 13, 3. P. 329335.

208. Gans, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation/ T. Gans// Blood. 2003. Vol. 102, 3. P. 783790.

209. Garcia-Manero, G. Hypomethylating agents and other novel strategies in myelodysplastic syndromes/ G. Garcia-Manero, P. Fenaux// J. Clin. Oncol. 2011.

Vol. 29, 5. P. 516523.

210. Goldberg, S.L. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes/ S.L. Goldberg// Leuk. Res. 2007. Vol.

31, Suppl 3. P. 1622.

211. Gora-Tybor, J. Targeted drugs in chronic myeloid leukemia/ J. Gora-Tybor, T.

Robak// Curr. Med. Chem. 2008. Vol. 15, 29. P. 30363051.

212. Greenberg, P.L. Apoptosis and its role in the in the myelodysplastic syndromes;

implications for disease natural history and treatment/ P.L. Greenberg// Leuk. Res. 1998. Vol. 22. P. 11231136.

213. Gritsaev, S. Selection of candidates for iron chelation therapy (ICT)/ S.

Gritsaev, B. Davaasambuu, N.A. Romanenko// EGM Iron Summit 2013/ Clinical practice strategies and new perspectives in hematology and iron science (Program Book). 2013. P. 30.

214. Hadland, B.K. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms/ B.K. Hadland, G.D. Longmore// J. Clin. Oncol. 2009. Vol. 25. P. 42174226.

215. Hematology Basic Principles and Practice/ R. Hoffman, E.J. Benz, J. Sanford [et al.]// Churchill Livingstone, London. 2000. P. 1294.

216. Henry, D.H. Guidelines and recommendations for the management of anemia in patients with lymphoid malignancies/ D.H. Henry// Drugs. 2007. Vol. 67, 2. P.

175194.

217. Hepcidin: a urinary antibacterial peptide synthesized in the liver/ C.H. Park, E.V. Valore, A.J. Waring [et al.]// J. Biol. Chem. 2001. Vol. 276. P. 78067810.

218. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM/ C. Kelaidi, O. BeyneRauzy, T. Braun [et al.]// Ann. Hematol. 2013. Vol. 92, 5. P. 621631.

219. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution/ A. Azzara, G. Carulli, S.

Galimberti [et al.]// Am. J. Hematol. 2011. Vol. 86, 9. P. 762767.

220. Hoffmann, M. Erythropoiesis stimulating agents/ M. Hoffmann, V. Schwenger// Ther. Umsch. 2011. Vol. 68, 11. P. 650654.

221. Huang, J. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level/ J. Huang, A. Tefferi// Europian Journal of Haematology. 2009.

Vol. 83, 2. P. 154155.

222. Huang, L.J. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor/ L.J. Huang, S.N.

Constantinescu, H.F. Lodish// Mol. Cell. 2001. Vol. 8, 6. P. 13271338.

223. Hunt, J.A. Half-life and rate of synthesis of globin messenger ribonucleic acid.

Determination of half-life messenger ribonucleic acid and its relative synthetic rate in erythroid cells/ J.A. Hunt/ Biochem. J. 1974. Vol. 138, 3. P. 487498.

224. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma/ E. Katodritou, E. Terpos, K. Zervas [et al.]//Ann. Hematol. 2007. Vol. 86, 5. P. 369376.

225. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression/ G. Acs, P.J. Zhang, C.M. Mc Grath [et al.]// Am. J. Pathol. 2003. Vol. 162, 6. P. 17891806.

226. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo/ E.B. Rankin, M.P. Biju, Q. Liu [et al.]// J. Clin. Invest. 2007. Vol. 117. P. 1068 1077.

227. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells/ S. Elliott, L. Busse, I. Mc Caffery [et al.]// J. Immunol. Methods. 2010. Vol. 352. P. 126139.

228. Identification of an intestinal haem transporter/ M. Shayeghi, G.O. LatundeDada, J.S. Oakhill [et al.]// Cell. 2005. Vol. 122. P. 789801.

229. IL-6 mediates hyppoferremia inducting the synthesis of the iron regulatory hormone hepcidin/ E. Nemeth, S. Rivera, V. Gabajan [et al.]// J. Clin. Inv. 2004. Vol. 113. P. 12711276.

230. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia/ S.G. O'Brien, F. Guilhot, R.A. Larson [et al.]// N. Engl. J. Med. 2003. Vol. 348. P. 9941004.

231. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study/ R. A., Larson, B. J. Druker, F. Guilhot [et al.]// Blood. 2008. Vol. 111, 8. P. 4022 4028.

232. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC/ S. Vadhan-Raj, X. Zhou, K. Sizer [et al.]// The Oncologist. 2010. Vol. 15. P. 1359 1369.

233. Implamentation of the full automated, multi-plexed nucleic acid testing at Qingdao blood center, China/ Z. Yand, L. Xu, L. Liu [et al.]// Vox Sang. 2012. Vol. 103, Suppl. 1. P. 152.

234. Increased expression of APAF-1 in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia/ B.D. Benites, F. Traina, S.

Duarte Ada [et al.]//Eur. J. Haematol. 2010. Vol. 84, 6. P. 525530.

235. Increased plasma viscosity as a reason for inappropriate erythropoietin formation/ A. Singh, K.U. Eckardt, A. Limmermann [et al.]// J. Clin. Invest. 1993. Vol. 91. P. 251256.

236. Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin inmyelodysplastic syndromes? A report on 59 cases/ R. Itzykson, S.

Ayari, D. Vassilief [et al.]// Leukemia. 2009. Vol. 23, 4. P. 673678.

237. Isolation and characterization of genomic and cDNA clones of human erythropoietin/ K. Jacobs, C. Shoemacer, R. Rudersdorf [et al.]// Nature. 1985. Vol. 313. P. 806810.

238. Jabbour, E. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia/ E. Jabbour, M. Deininger, A.

Hochhaus// Leukemia. 2011. Vol. 25. P. 201210.

239. Klein, H.G. Red Blood Cell Transfusion in clinical practice/ H.G. Klein, D.R.

Spahn, J.L. Carson// Lancet. 2007. Vol. 370. P. 415426.

240. Kumral, A. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats/ A. Kumral, N. Uysal, K.

Tugyan [et al.]// Behav. Brain Res. 2004. Vol. 153, 1. P. 7786.

241. Lack of functional erythropoietin receptors of cancer cell lines/ M. Laugsch, E.

Metzen, T. Svensson [et al.]// Int. J. Cancer. 2008. Vol. 122, 5. P. 10051011.

242. Leitch, H.A. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?// H.A. Leitch, L.M. Vickars// Hematology Am. Soc. Hematol.

Educ. Program. 2009. H. 664672.

243. Littelwood, T.J. Influence of the maintenance of hemoglobin of blood on results of treatment of patients with malignant disease/ T.J. Littelwood// Seminars of Oncology. 2001. Vol.28, 2, Suppl. 8. P. 4953.

244. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin +13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival/ E. Cris, C. Foli, R. Passera [et al.]// Br. J. Haematol. 2012. Vol. 158, 1. P. 99107.

245. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib/ F.P.

Santos, Y. Alvarado, H. Kantarjian [et al.]// Cancer. 2011. Vol. 117, 5. P. 982 991.

246. Ludwig, H. Anemia in Cancer patients/ H. Ludwig, E. Fritz// Semn Oncol. 1998. Vol. 25, 3, Suppl. 7. P. 26.

247. Ludwig, H. Anemia in multiple myeloma/ H. Ludwig, G. Pohl, A. Osterborg// Clin. Adv. Hematol. Oncol. 2004. Vol. 2, 4. P. 233241.

248. Ludwig, H. Anemia of hematologic malignancies: what are the treatment options?/ H. Ludwig// Semin. Oncol. 2002. Vol. 29, 3, Suppl. 8. P. 4554.

249. Macdougall, I. Novel erythropoiesis-stimulating agents: a new era in anemia management/ I. Macdougall// Clin. J. Am. Soc. Nephrol. 2008. Vol. 3, 1. P.

200207.

250. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations/ H. Ludwig, K.

Rai, J. Blade [et al.]// Hematol. J. 2002. Vol. 3, 3. P. 121130.

251. Mauro, F.R. Erythropoietin and chronic lymphocytic leukemia/ F.R. Mauro, M.

Gentile, R. Foa// Rev. Clin. Exp. Hematol. 2002. 1. P. 2131.

252. Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?/ M.R. Song, J.S. Chung, Y.M. Seol [et al.]// Leuk. Res. 2009. Vol. 33, 11. P. 14591459.

253. Measuring fatigue, and other anemia related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system/ S.B. Yellen, D.F. Cella, K. Webster [et al.]// J. Pain Symptom Manage. 1997. Vol. 13. P. 6374.

254. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapyinduced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials/ Y. Ohashi, Y. Uemura, Y. Fujisaka [et al.]// Cancer Sci. 2013. Vol. 104,4. P. 481485.

255. Mittelman, M. The implications of anemia in multiple myeloma/ M. Mittelman// Clin. Lymphoma. 2003. Vol. 4, Suppl 1. S. 2329.

256. NCCN Cancer-related Fatigue Panel: National Comprehensive Cancer Network.

Clinical practice Guidelines in Oncology [ ]/ Distress Management Version 1, 2006 / www.nccn.org /.

257. No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo/ Y. Sasaki, E. Kjellen, H.

Mineta [et al.]// Acta Oncol. 2009. Vol. 48, 7. P. 10621069.

258. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin Production/ M. Cazzola, Y. Beguin, J. Kloczko [et al.]// Br. J. Haematol. 2003. Vol. 122,3. P. 386393.

259. Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study/ Y.

Morishima, M. Ogura, S. Yoneda [et al.]// Jpn. J. Clin. Oncol. 2006. Vol. 36, 10.

P. 655661.

260. One thousand patients with primary myelofibrosis: the mayo clinic experience/ A. Tefferi, T.L. Lasho, T. Jimma [et al.]// Mayo. Clin. Proc. 2012. Vol. 87, 1. P. 2533.

261. Orphanos, G.S. Cardiotoxicity induced by tyrosine kinas inhibitors/ G.S.

Orphanos, G.N. Ioannidis, A.G. Ardavanis// Acta Oncol. 2009. Vol. 48, 7. P.

964970.

262. Osterborg, A. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy/ A. Osterborg, J.L. Steegmann, A.

Hellmann// Br. J. Haematol. 2007. Vol. 136, 5. P. 736744.

263. Oxford Handbook of Clinical Haematology/ D. Provan, C.R.J. Singer, T. Baglin, I. Dokal// Oxford University Press, Third edition (2009). 2012. 820 P.

264. Papayannopoulono, T. Biology of erythropoiesis, erythroid maturation and differentiation/ T. Papayannopoulono, J. Abkowitz, A. DAndrea/ In: Hoffman R., Benz E.J., Shattil S.J. [et al.] editors Hematology Basic Principals and Practice. 3 rd ed.

Philadelphia: Churchill Livingston. 2000. P. 202219.

265. Patients with cancer/ A. Nicolaides, J.Fareed, A.K. Kakkar [et al.]// Clin. Appl.

Thromb Hemost. 2013. Vol. 19, 2. P. 172176.

266. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer/ D.L. Hershman, D.L. Buono, J. Malin [et al.]// J. Natl. Cancer Inst. 2009. Vol. 101, 23. P. 16331641.

267. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease/ I. Macdougall, R. Robson, S. Opatrna [et al.]// Clin. J. Am. Soc. Nephrol. 2006. Vol. 1. P. 12111215.

268. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia/ D.P. Steensma, J.A. Sloan, S.R. Dakhil [et al.]// J.

Clin. Oncol. 2011. Vol. 29, 1. P. 97105.

269. Pierce, C.N. Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device/ C.N. Pierce, D.F. Larson/ Perfusion. 2005. Vol. 20, 2. P. 8390.

270. Plasma cell leukemia with myelofibrosis/ T. Murayama, T. Matsui, Y. Hayashi [et al.]// Ann Hematol. 1994. Vol. 69, 3. P. 151152.

271. Pooled analysis of individual patient-level data from all randomized, doubleblind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia/ H. Ludwig, J. Crawford, A. Osterborg [et al.]// J. of clin. Oncol. 2009. Vol. 27, 17. P. 28382847.

272. Population-based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma/ P.T. Truong, T. Parhar, J. Hart [et al.]// Am. J. Clin. Oncol. 2010. Vol. 33, 5. P. 465468.

273. Preconditioning with erythropoietin protects against subsequent ischemiareperfusion injury in rat kidney/ C.W. Yang, C. Li, J.Y. Jung [et al.]// FASEB J. 2003. Vol. 17, 12. P. 17541755.

274. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience/ S. Park, S. Grabar, C. Kelaidi [et al.]// Blood. 2008. Vol. 111, 2. P. 574582.

275. Prevalence and incidence of HIF infaction at five Cginese blood centers/ J.Wang, J. Liu, T. Yang [et al.]// Vox Sang. 2012. Vol. 103, Suppl. 1. P. 18.

276. Production and characterization of anti-recombinant human erythropoietin (rhEPO) monoclonal antibody/ J. Yan, S. Wang, J.B. Mi [et al.]// J. Immunoassay Immunochem. 2004. Vol. 25, 1. P. 91101.

277. Prognostic factors and life expentancy in myelodysplastic syndromes classified according to WHO criteria: a basic of clinical decision making/ L.Malcovati, M.P.

Porta, C. Pascito [et al]// J. Clin. Oncol. 2005. Vol. 23. P. 759475603.

278. Prognostic value of hemoglobin concentration in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery/ W. Wagner, R. Hermann, J. Hartlapp [et al.]/ Strahlentherapie und Onkologie. 2000. Vol. 76. P. 7380.

279. Progressive inactivation of the expression of an erythroid transcriptional factor in GM- and G-CSF-dependent myeloid cell lines/ S. Crotta, S. Nicolis, A. Ronchi [et al.]// Nucleic Acids Res. 1990. Vol. 18, 23. P. 68636869.

280. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of 120 g/L with darbepoetin alfa filgrastim or erythrocyte transfusions/ H. Nisson-Echle, G. Birgegrd, J. Samuelsson [et al.]// Eur. J.

Haematol. 2011. Vol. 87, 3. P. 244252.

281. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies/ D.J. Straus, M.A. Testa, B.J. Sarokhan [et al.]// Cancer. 2006. Vol.

107, 8. P.19091917.

282. Ramchandren, R. Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia/ R. Ramchandren, C.A. Schiffer// Biologics. 2009. 3. P.

205214.

283. Randomized, double-blind, placebo-controlled trial of erythropoietin in nonsmall-cell lung cancer with disease-related anemia/ J.R. Wright, Y.C. Ung, J.A. Julian [et al.]// J. Clin. Oncol. 2007. Vol. 25, 9. P. 10271032.

284. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies/ A. Osterborg, Y.

Brandberg, V. Molostova [et al.]// J. Clin. Oncol. 2002. Vol. 20, 10. P. 2486 2494.

285. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia/ L. Bastit, A. Vandebroek, S. Altintas [et al.]// J. Clin. Oncol. 2008. Vol. 26, 10. P. 16111618.

286. Ratcliffe, P.J. HIF-1 and HIF-2: working alone or together in hypoxia?/ P.J.

Ratcliffe// J. Clin. Invest. 2007. Vol. 117, 4. P. 862865.

287. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials/ J. Bohlius, K. Schmidlin, C. Brillant [et al.]// Lancet. 2009. Vol. 373. P. 15321542.

288. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma/ A. Osterborg, M.A. Boogaerts, R.

Cimino [et al.]// Blood. 1996. Vol. 87, 7. P. 26752682.

289. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment/ F. Baron, P.

Frre, G. Fillet, Y. Beguin// Clin. Cancer. Res. 2003. Vol. 9, 15. P. 55665572.

290. Recombinant human erythropoietin : the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients/ O. Durmaz, M Demirkaya, B. Sevinir// Pediatr. Hematol. Oncol. 2011. Vol. 28, 6. P. 461 468.

291. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy results of a randomized trial/ J.P. Glossmann, A. Engert, G. Wassmer [et al.]// Ann. Hematol. 2003. Vol. 82, 8. P. 469475.

292. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients/ J. Bohlius, J. Wilson, J. Seidenfeld [et al.]// J.

Natl. Cancer Inst. 2006. Vol. 98. 10. P. 708714.

293. Regulation of hepcidin and ferroportin expression by lipopolysaccharide in splenic macrophages/ X.B. Liu, N.B. Nguyen, K.D. Marquess [et al.]// Blood Cells Mol. Dis. 2005. Vol. 35. P. 4756.

294. Regulation of hepcidin transcription by interleukin-1 and interleukin-6/ P. Lee, H. Peng, T. Gelbart [et al.]// Proc. Nat. Acad. Sci. USA. 2005. Vol. 102. P.

19061910.

295. Regulation of iron homeostasis by the hypoxia-inducible factors (HIFs)/ C.

Peyssonnaux, A. Zinkernagel, R. Schuepbach, R. Johnson// J. Clin. Invest. 2007. Vol. 117, 7. P. 19261932.

296. Report of an international working group to standardize response criteria for myelodysplastic syndromes/ B.D. Cheson, J.M. Bennett, H. Kantarjian [et al.]// Blood.

2000. Vol. 96, 12. P. 36713674.

297. Report of the Committee on Hodgkins disease staging classification/ P.P.

Carbone, H.S. Kaplan, K. Musshof [et al.]// Cancer research. 1971. Vol. 31. P.

18601861.

298. Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface/ A.R. Migliaccio, G. Migliaccio, A. DAndrea [et al.]// Proc. Natl. Acad. Sci.

USA. 1991. Vol. 88, 24. P. 1108611090.

299. Retrospective nationwide survey of Japanese patients with transfusiondependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality/ M. Takatoku, T. Uchiyama, S. Okamoto [et al.]// Eur. J.

Haematol. 2007. Vol. 78. 487494.

300. rHuEPO and improved treatment outcomes: potential modes of action/ K.

Blackwell, P. Gascn, G. Sigounas, L. Jolliffe// Oncologist. 2004. Vol. 9, Suppl. 5.

P. 4147.

301. rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study/ M. Hunault-Berger, A.

Tanguy-Schmidt, P. Rachieru [et al.]// Bone Marrow Transplant. 2005. Vol. 35, 9. P. 903907.

302. Ribatti, D. Erythropoietin and tumor angiogenesis/ D. Ribatti// Stem Cells Dev.

2010. Vol. 19, 1. P. 14.

303. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells/ G. Paragh, S.M. Kumar, Z. Rakosy [et al.]// Am. J. Pathol. 2009. Vol. 174, 4. P. 15041514.

304. Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy/ P.L. Zinzani, M. Tani, L. Alinari [et al.]// Leuk.

Lymphoma. 2005. Vol. 46, 10. P. 14491454.

305. Roy, C.N. Iron homeostasis: new tales from the cyipt/ C.N. Roy, C.A. Enns// Blood. 2000. Vol. 96, 13. P. 40204027.

306. Safety and efficacy of recombinant human erythropoietin treatment of anemia associated with multiple myeloma in haemodialysed patients/ P. Ruedin, B. Bertschi, W. Chapais [et al.]// Nephrol. Dial. Transplant. 1993. Vol. 8, 4. P. 315318.

307. Salek, S. EHA SWG Quality of Life and Symptoms Patients needs in hematology: whose perspectives?/ S. Salek, T. Ionova, E. Oliva// Haematologica. 20134. Vol. 98, Suppl. 6. P. 828830.

308. Samuelsson, J. Long-standing resolution of anemia in symptomatic low-grade non-Hodgkin's lymphoma patients treated with recombinant human erythropoietin as sole therapy / J. Samuelsson // Med Oncol. 2002. Vol. 19, 1. P. 6972.

309. Santini, V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes/ V. Santini// Oncologist. 2011. Vol. 16, Suppl. 3. P. 3542.

310. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinas inhibitors/ X.

Huang, S. Patel, N. Ahmed [et al.]/ Drug Des Devel Ther. 2009. 2. P. 215219.

311. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia/ A. Hochhaus, S.G. O'Brien, F. Guilhot [et al.]// Leukemia.

2009. Vol. 23, 6. P.10541061.

312. Smith, T.G. The human side of hypoxia-inducible factor/ T.G. Smith, P.A.

Robbins, P.J. Ratcliffe// Br. J. Haematol. 2008. Vol. 141, 3. - P. 325334.

313. Snow, J.W. Translational isoforms of FOG1 regulate GATA1-interacting complexes/ J.W. Snow, S.H. Orkin// J. Biol. Chem. 2009. Vol. 284, 43. P.

2931029319.

314. Steinbrook, R. Medicare and erythropoietin/ R. Steinbrook// N. Engl. J. Med. 2007. Vol. 356, 1. P. 46.

315. Steurer, M. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey/ M. Steurer, H. Wagner, G. Gastel// Wien. Klin. Wochenschr. 2004. Vol. 116, 11-12. P. 367372.

316. Straus, D.J. Epoetin alfa therapy for parameters with hematologic malignancies and mild anemia/ D.J. Straus// Clin. Lymphoma. 2003. Vol. 4, Suppl. 1. S. 13 17.

317. Structure-function correlation in erythropoietin formation and oxygen sensing in the kidney/ M. LeHir, K.U. Eckardt, B. Kaissling [et al.]// Klin. Wochenschr. 1991.

Vol. 69, 13. P. 567575.

318. Study on serum erythropoietin levels in patients with hematologic malignancies/ B. Han, Y.K Shi, J. Zhu [et al.]// Zhonghua Xue Ye Xue Za Zhi. 2006. Vol. 27, 8. P. 543545.

319. Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for highdose chemotherapy without support of allogeneic blood products/ S. Schmitt, V.

Mailaender, G. Egerer [et al.]// Int. J. Hematol. 2008. Vol. 87, 3. P. 289297.

320. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study/ R.

Delarue, C. Haioun, B. Coiffier [et al.]// J. Clin. Oncol. 2011. Vol. 29 (suppl.; abstr 9048).

321. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes/ J.M.

Vardiman, J. Thiele, D.A. Arber [et al.]// Blood. 2009. Vol. 114, 5. P. 937 951.

322. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy/ F. Dammacco, F. Silvestris, G.L. Castoldi [et al.]/ Int. J. Clin. Lab. Res. 1998. Vol. 28, 2. P. 127134.

323. The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase/ Q. Jiang, S.S. Chen, B. Jiang [et al.]// Zhonghua Xue Ye Xue Za Zhi. 2007. Vol. 28, 11. P. 721726.

324. The erythropoietin receptor in normal and cancer tissues/ W. Jelkmann, J.

Bohlius, M. Hallek, A.J. Sytkowski// Crit. Rev. Oncol. Hematol. 2008. Vol. 67, 1. P. 3961.

325. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation/ G. Nicolas, C. Chauvet, L. Viatte [et al.]// J. Clin. Inv. 2002. Vol. 110. P. 10371044.

326. The gene ofor the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p/ J.C. Winkelmann, L.A. Penny, L.L.

Deaven [et al.]// Blood. 1990. Vol. 76, 1. P. 2430.

327. The HIF hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity/ N. Masson, R.S. Singleton, R. Sekirnik [et al.]// EMBO Rep. 2012. Vol. 13, 3. P. 251257.

328. The impact of hemoglobin levels on fatigue and quality of life in cancer patients/ B. Holzner, G. Kemmler, R. Greil [et al.]// Ann. Oncol. 2002. Vol. 13. P. 965973.

329. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life/ M. Lind, C. Vernon, D. Cruickshank [et al.]// Br. J. Cancer. 2002. Vol. 86. P. 12431249.

330. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory/ T.R.Mendoza, X.S. Wang, C.S. Cleeland, [et al.]// Cancer. 1999.

Vol. 85, 5. P. 11861196.

331. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. From clinic to bench a critical review/ J. Szenajch, G. Wcislo, J.Y. Jeong [et al.]// Biochim. Biophys. Acta. 2010. Vol. 1806. Vol. 1.

P. 8295.

332. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma/ F. Dammacco, G. Luccarelli, M. Prete, F. Silvestris/ Rev. Clin. Exp. Hematol. 2002. Suppl 1. P. 3238.

333. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review/ N. Shehata, I. Walker, R. Meyer [et al.]// Ann. Hematol. 2008. Vol. 87, 12. P. 961973.

334. Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects/ W.Y. Zou, D.R. Xu, C. Su [et al.]// Nan Fang Yi Ke Da Xue Xue Bao. 2008. Vol. 28, 9. P.16601662.

335. Time-course analysis of hepcidin, serum iron and plasma cytokine levels injected with LPS/ E. Kemna, P. Pickers, E. Nemeth [et al.]// Blood. 2005. Vol.

106, 5. P. 18641866.

336. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia/ S. Picard, K. Titier, G. Etienne [et al.]// Blood. 2007. Vol. 109. P. 34963499.

337. Tumor Hypoxia has independent predictor impact only in patients with nodnegative cervix cancer/ A. Fules, M. Milosevic, D. Hedley [et al.]// J. Clin. Oncol. 2002. Vol. 20. P. 680687.

338. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation/ I. Buck, F. Morceau, S.

Cristofanon [et al.]// Biochem Pharmacol. 2008. Vol. 76, 10. P. 12291239.

339. Tyrosine kinase inhibitors and solid tumours: case report and review of the literature/ F. Roszkiewicz, R. Garidi, I. Vaida [et al.]// Pharmacology. 2009. Vol.

84, 1. P. 3841.

340. Urao, N. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia/ N. Urao, M. Okigaki, H. Yamada// Circ. Res. 2006. Vol.

98. P. 14051413.

341. Vardiman, J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms/ J.W. Vardiman// Chem. Biol. Interact. 2010. Vol. 184, 1-2. P. 16 20.

342. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia/ C.L. Bennett, S.M. Silver, B. Djulbegovic [et al.]// JAMA. 2008. Vol.

299, 8. P. 914924.

343. Wang, T. The role of cytokines in lymphoma with anemia/ T. Wang, M.F. Tu, J.

Zhu// Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013. Vol. 21, 2. P. 392395.

344. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebocontrolled study/ M. Tsuboi, K. Ezaki, K. Tobinai [et al.]// Jpn. J. Clin. Oncol. 2009.

Vol. 39, 3. P. 163168.

345. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy/ Y. Suzuki, Y.

Tokuda, Y. Fujiwara [et al.]// Jpn. J. Clin. Oncol. 2008. Vol. 38, 3. P. 214 221.



Pages:     | 1 |   ...   | 2 | 3 ||
:

. . : 1 -...

03.00.03 2006 ...

. . , . . . . -, , ...

. . ...

579.6 .. , .. , .. -, . , . , 32, 450074 , - ...

~1~ " , " ...

. . 2014. 1 (25). . 132153 575.16 doi: 10.17223/19988591/25/10 .. 1, .. 2 , . , , . , - GAGA...

, 619.576.894:895.131 .. ...

.. .., .., .., . ...










 
<<     |    
2017 www.lib.knigi-x.ru - -

, .
, , , , 1-2 .